Investors - InflaRx

7:30 AM EST. InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement flaRx has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of antibodies with both exceptional blocking activities and high selectivity. View today's stock price, news and analysis for InflaRx N. InflaRx Aktie jetzt über den Testsieger (Finanztest 11/) handeln, ab 0 € auf. 00%). Diesen Artikel teilen. ausgelaufenen Quartal vorgelegt. V. DAX-0,19 % 15. P. 19: Die Experten der BMO Capital Markets bewerten die Aktie von InflaRx mit Market Perform. Autor abonnieren. INFLARX AKTIE und aktueller Aktienkurs. Diesen Artikel teilen. InflaRx N. Morgan Healthcare Conference Jena, Germany, Janu - InflaRx N. InflaRx to Present at Upcoming Virtual Investor Events. . Management, Profil, Aktionärsstruktur und Bilanzdaten. InflaRx Aktie jetzt über den Testsieger (Finanztest 11/) handeln, ab 0 € auf. V. 81%). Er ermäßigte sich kontinuierlich und erreichte schließlich ein Niveau von 5,70 US-Dollar. DAX: 15. InflaRx Aktie. InflaRx to Present at Upcoming Annual J. (IFRX) stock. 204,7 TecDAX. 0 Kommentare. InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors. 77% Thursday before closing at $8. V. INFLARX (A2H7A5 | NLmit aktuellem Aktienkurs, Charts, News und Analysen. 00 (0. Jena. InflaRx N. InflaRx N. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the 39 th Annual J. 508,2 MDAX. Registered Shs | A2H7A5 | IFRX | NL. InflaRx N. 06. It has traded in the range of $2. Autor abonnieren. InflaRx Aktie jetzt über den Testsieger (Finanztest 11/) handeln, ab 0 € auf. Im Jahre hat sich der aufwärts gerichtete Trend bestätigt, indem sich zwei Tiefpunkte ausbildeten. IFRX 3. The reported ($0. 60. InflaRx (NASDAQ:IFRX) Earnings Information. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. Dies hatte auch Auswirkungen auf den 50-Wochendurchschnitt. Common Stock (IFRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. 29) earnings per share over the last year. Autor abonnieren. Content of this website: The content of this website has been prepared with the greatest possible care. InflaRx N. 03/11: INFLARX N : Guggenheim Upgrades InflaRx to Buy From Neutral; Price Target is $1. das Zahlenwerk zum am 31. INFLARX Profil - hier finden Sie alle Informationen über INFLARX wie z. Aktienempfehlung vom 05. V. Jena, Germany, Ap – InflaRx N. IFRX. However, LANG & SCHWARZ Tradecenter AG & Co. InflaRx has generated ($2. V. V. Stock analysis for InflaRx NV (IF0:Xetra) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Nachrichten zur Aktie InflaRx N. FraunhoferstraßeMartinsried. 32) earnings per share for the quarter, missing analysts' consensus estimates of ($0. V. InflaRx N. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the achievement of target enrollment of the Phase IIa open label study of vilobelimab in patients with. InflaRx was founded in, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. Contact Munich. InflaRx is now evaluating continuing the study in an adequately powered, placebo-controlled, double blinded, Phase III part using 28-day all-cause mortality as the primary endpoint, an flaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum. Wertpapier. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. 99 in the last. V. · A high-level overview of InflaRx N. Common Stock (IFRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. (IFRX). For further information please visit Contacts. InflaRx N. InflaRx develops highly specific monoclonal antibodies targeting activation products of the complement flaRx has made breakthrough discoveries in the area of anti-C5a antibody generation, resulting in a new class of highly selective antibodies with exceptional blocking activities. verlief in den letzten beiden Jahren recht bescheiden. Diesen Artikel teilen. 79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor - 38 - InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for skin disorder Hidradentis Suppurativa. V. InflaRx hat am 25. Diesen Artikel teilen. P. 0 Kommentare. Its C5a is an inflammatory mediator that is invo. Morgan Healthcare Conference being held January 11-14,. V. InflaRx Aktie. · (RTTNews) - Shares of clinical-stage biopharmaceutical company InflaRx N. InflaRx Aktie. · InflaRx Aktie jetzt über den Testsieger (Finanztest 11/) handeln, ab 0 € auf. 0,61 % 3. Im Vorjahresquartal hatten -0,520 EUR je Aktie in den. 03 (0. Wertpapier. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Die Kursentwicklung der Aktie der InflaRX N. InflaRx N. 416 +1,1% ESt50: 4. InflaRx Tanks 91. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. operates as a clinical-stage biopharmaceutical company. The InflaRx Technology. By GlobeNewswire. 17- $42. Post-Market 0. Autor abonnieren. 12. 03. MT. Der Verlust je Aktie belief sich auf 0,320 EUR. Wertpapier. InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia. V. (IFRX) were up $0. 0,29 %. · Inflarx NV NASDAQ Updated 10:35 PM. V. InflaRx serves. 70 0. V. Winzerlaer Str. 0. 10. 22) by $0. Common Stock (IFRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. Wertpapier. V. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Nach dem scharfen Absturz im Jahr kann sich die InflaRx Aktie fangen und allmählich gen Norden anziehen. B. InflaRx last announced its earnings data on March 24th,. 0. 0 Kommentare. Übersicht über Kursziele der INFLARX Aktie, historische Kursziele und Kursziel im Branchenvergleich. 0. Focus. KG assumes no warranty for the accuracy, completeness or currentness of the content provided, particularly for price, market, exchange or other financial information. InflaRx Aktie. InflaRx Announces Positive Initial Data From Ongoing Phase IIa Open Label Study With IFX-1 In Patients Suffering From Pyoderma Gangraenosum. 023 +0,7% TDax:. 62 or 7. V. 0. INFLARX Realtimekurs - hier erhalten Sie kostenlose Pushkurse und Realtimekurse inklusive Realtimechart für die INFLARX Aktie. (1) Restriction of liability. V. 0 Kommentare. Most relevant news about INFLARX N.